These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32041715)

  • 1. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
    Illamola SM; Colom H; van Hasselt JG
    Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
    Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
    Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.
    Bleyzac N; Varnier V; Labaune JM; Corvaisier S; Maire P; Jelliffe RW; Putet G; Aulagner G
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):499-504. PubMed ID: 11699615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
    Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
    Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of renal function equations to predict amikacin clearance.
    Sáez Fernández EM; Pérez-Blanco JS; Lanao JM; Calvo MV; Martín-Suárez A
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):805-813. PubMed ID: 31242039
    [No Abstract]   [Full Text] [Related]  

  • 18. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
    Caceres Guido P; Perez M; Halac A; Ferrari M; Ibarra M; Licciardone N; Castaños C; Gravina LP; Jimenez C; Garcia Bournissen F; Schaiquevich P
    Pediatr Pulmonol; 2019 Nov; 54(11):1801-1810. PubMed ID: 31402602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.
    Akers KS; Cota JM; Frei CR; Chung KK; Mende K; Murray CK
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4639-42. PubMed ID: 21825289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.